Biliary Cholangitis
📧 Sign up to get email alerts when something new happens for Biliary Cholangitis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Clinical Characterization of Patients With Primary Biliary Cirrhosis Treated With Seladelpar in the Real-life Setting
This clinical trial update describes the real-world characterization of patients with primary biliary cholangitis treated with seladelpar, w…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment
Ipsen is conducting a clinical study to observe the everyday effectiveness and safety of Elafibranor in participants with Primary Biliary Ch…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis [Phase 3]
Ipsen's long-term Phase 3 trial is evaluating elafibranor in adults with primary biliary cholangitis and is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC) [Phase 3]
Phase 3 study evaluating elafibranor in adult Japanese participants with Primary Biliary Cholangitis; the trial is currently active but not …
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. [Phase 3]
This is a Phase 3 clinical trial update for elafibranor in adults with primary biliary cholangitis; the study investigates those with inadeq…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome
A recruiting clinical trial is examining the liver-gut axis by identifying liver disease–specific microbiome patterns. The study covers auto…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis) [Phase 2]
A Phase 2 clinical trial of CS0159 for primary biliary cholangitis in Chinese patients is currently active but not recruiting, sponsored by …
-
CLINICAL_TRIALS research · 2026-03-09Clinical Trial Update: A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction [Phase 1, Phase 2]
This clinical trial update describes a two-part Phase 1/Phase 2 study evaluating two doses of golexanolone in adults with primary biliary ch…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy [Phase 3]
A Phase 3 clinical trial studying saroglitazar magnesium for Primary Biliary Cholangitis patients who have incomplete response or intoleranc…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis
A 5-year longitudinal observational study of patients with primary biliary cholangitis has completed, sponsored by Target PharmaSolutions, I…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes [Phase 3]
Phase 3 long-term study to evaluate the safety and efficacy of Saroglitazar Magnesium-V in participants with Primary Biliary Cholangitis; tr…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Biobank for Cholestatic Liver Diseases.
Mayo Clinic is recruiting for a biobank study of cholestatic liver diseases, including primary sclerosing cholangitis and primary biliary ch…
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis [Phase 3]
An open-label extension study (Phase 3) of saroglitazar magnesium in participants with primary biliary cholangitis, currently recruiting.
-
CLINICAL_TRIALS research · 2026-01-08Clinical Trial Update: Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis [Phase 2, Phase 3]
This clinical trial update describes a Phase 2/Phase 3 study evaluating fenofibrate in combination with ursodeoxycholic acid for primary bil…
-
CLINICAL_TRIALS research · 2026-01-08Clinical Trial Update: Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study [Phase 3]
A real-world Phase 3 trial evaluating fenofibrate in combination with ursodeoxycholic acid for primary biliary cholangitis is currently recr…
-
CLINICAL_TRIALS research · 2026-01-08Clinical Trial Update: Fenofibrate in Primary Biliary Cholangitis: a Real World Study [Phase 3]
A Phase 3 real-world study evaluating fenofibrate for primary biliary cholangitis is currently recruiting, led by Xijing Hospital of Digesti…
-
CLINICAL_TRIALS research · 2026-01-08Clinical Trial Update: Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis [Phase 2, Phase 3]
A Phase 2/Phase 3 clinical trial is evaluating fenofibrate in patients with compensated cirrhosis due to primary biliary cholangitis and is …
-
CLINICAL_TRIALS research · 2026-01-08Clinical Trial Update: Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis [Phase 3]
This clinical trial update notes a Phase 3 study evaluating fenofibrate combined with ursodeoxycholic acid in subjects with Primary Biliary …
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: The Value of Spleen Stiffness Measurement in Patients With PBC [NA]
This clinical trial update notes a study evaluating spleen stiffness measurement in patients with primary biliary cholangitis, which is curr…
-
CLINICAL_TRIALS research · 2025-12-30Clinical Trial Update: A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA [Phase 3]
This clinical trial update notes that CS0159 is in Phase 3 testing for primary biliary cholangitis patients with inadequate response or into…
-
CLINICAL_TRIALS research · 2025-12-29Clinical Trial Update: FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy [Phase 3]
A Phase 3 FIREFLY trial evaluating fenofibrate as first-line therapy for Primary Biliary Cholangitis is currently recruiting. The trial is s…
-
CLINICAL_TRIALS research · 2025-12-23Clinical Trial Update: Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC) [Phase 3]
Phase 3 trial update for seladelpar in primary biliary cholangitis; the study is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2025-11-28Clinical Trial Update: A Multicenter, Randomized, Controlled Trial of Prednisone Combined With Ursodeoxycholic Acid in the Treatment of Primary Biliary Cholangitis With Moderate to Severe Interface Hepatitis Characteristics [Phase 2, Phase 3]
A multicenter randomized trial evaluates prednisone combined with ursodeoxycholic acid for primary biliary cholangitis with moderate to seve…
-
CLINICAL_TRIALS research · 2025-10-03Clinical Trial Update: Early Diagnosis of Primary Biliary Cholangitis (PBC) in Patients With Positive Anti-Mitochondrial Antibodies (AMA) and Normal Alkaline Phosphatase (ALP)
This clinical trial is currently recruiting to evaluate early diagnosis of Primary Biliary Cholangitis in patients with positive anti-mitoch…
-
CLINICAL_TRIALS research · 2025-09-10Clinical Trial Update: Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment. [Phase 2]
A Phase 2 clinical trial update evaluating pemafibrate (K-808) for primary biliary cholangitis in patients with inadequate response to UDCA …